Latest filing published 15 Sept 2026 for Neurocrine Biosciences INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Julie Cooke on record concern Neurocrine Biosciences Inc, in the capacity of senior executive. Between 4 October 2021 and 11 September 2026, the trades on record add up to 33 filings.
Every open-market trade on record is a sale: 18 sales worth €7.2M. Other entries cover 2 share grants and 13 option exercises. So far in 2026, the count stands at no purchases and 5 sales.
The latest filing, published on 15 September 2026, reports a share grant in Neurocrine Biosciences Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 33 declarations